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Dear editor
In the recently published paper by Zhang et al1 in Drug Des Develop Ther, the authors 
have evaluated the role of signal transducer and activator of transcription 3 (STAT3) 
in the antifibrotic activity of paclitaxel in vitro and in mice. They have reported that 
the treatment of paclitaxel at 2–4 µM reduced the level of phosphorylated STAT3 
at Tyr705 in a dose- and time-dependent manner, and downregulated the expression 
of fibronectin, α-smooth muscle actin (α-SMA), and collagen I in cultured rat renal 
interstitial fibroblast NRK-49F cells derived from normal kidney. Treatment of the 
cells with the selective STAT3 inhibitor S3I-201 at 50 mM suppressed the expression 
of fibronectin, α-SMA, and collagen I in NRK-49F cells. However, S3I-201 treat-
ment increased the expression of phosphorylated STAT1 but did not affect that of 
phosphorylated STAT5M. The immunoprecipitation assay has revealed that paclitaxel 
inhibited the STAT3 activity by disrupting the binding of STAT3 with tubulin inde-
pendently of the effect on STAT3 phosphorylation and by inhibiting STAT3 nucleus 
translocation.1 Furthermore, paclitaxel treatment by intraperitoneal injection at 
0.3 mg/kg twice a week ameliorated renal interstitial fibrosis by inhibiting the expres-
sion of fibronectin, α-SMA, and collagen I in a male C57 mouse model of unilateral 
ureteral obstruction. Paclitaxel administration also suppressed the infiltration of mac-
rophages and neutrophils and production of tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β, transforming growth factor (TGF)-β, and intercellular adhesion molecule 1 
(ICAM-1) by inhibition of STAT3 activity in mouse obstructive nephropathy.1 These 
findings indicate that paclitaxel suppresses renal interstitial fibrosis via inhibition of 
STAT3-mediated pathway and production of proinflammatory cytokines. The findings 
from this study indicate that in addition to being a clinically used anticancer agent, 
paclitaxel may represent a new agent that manages renal fibrosis.
Through indication discovery or therapeutic switching, drugs that have been 
approved for clinical use may be used for new indications, and this process is called 
drug repositioning or drug repurposing.2–7 Drug repositioning is different from drug 
coincidence or “serendipity”, which arises from unintentional mishaps in the drug 
discovery process as exemplified by drugs such as sildenafil and thalidomide. Apart 
from the staggering manufacturing cost and time reduction, drug repositioning 
facilitates drug discovery that will overcome bottlenecks in the therapeutic develop-
ment process and prolong patent life, thereby obtaining largest investment return 
throughout the development process coupled with a significantly higher rate of suc-
cess and reduced development risk. The benefits of drug repositioning for patients 
are evident in that newly arising diseases such as severe acute respiratory syndrome 
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and Middle East respiratory syndrome that threaten human 
beings can be treated by existing drugs with established 
pharmacokinetic, formulation, and safety data in animals and 
humans where specific repositioning potential is displayed 
in the associated references.4,8 As such, drug repositioning 
may tremendously decrease the overall development time to 
3–12 years and decrease total cost and attrition rates. There 
are increasing numbers of successes in drug repositioning. 
For example, colesevelam as a bile acid sequestrant was 
originally developed as an adjunct to diet and exercise to 
decrease elevated low-density lipoprotein cholesterol in 
patients with primary hyperlipidemia as monotherapy, but it 
has also gained approval from the Food and Drug Administra-
tion (FDA) to treat type 2 diabetes mellitus with unknown 
mechanism of action.9–11 Gabapentin and pregabalin were 
both originally developed as antiepileptic agents; they have 
been approved by the FDA to treat anxiety disorders and 
neuropathic pain.12–14
There are multiple technical approaches for drug reposi-
tioning. The disease- and drug-derived approaches employ 
available data related to diseases and knowledge of how 
drugs interact with the biological systems at molecular 
and cellular levels to identify potential new indications 
for existing drugs.2,6,7 Computational methods have been 
widely applied to explore drug–protein interactomes, drug 
off-targets, and adverse drug effects that can provide clues 
of new indications. Furthermore, genome-wide association 
studies (GWAS), medical genetics, and data from systems 
biological approaches have been used to conduct drug 
repositioning.15–21 GWAS data provide insights into the 
biology and pathology of diseases via bioinformatic net-
work analysis, which may be translated into potential new 
therapeutic targets that can be hit by approved drugs. Since 
pathologies are often shared between diseases, existing 
drugs against known targets can be retested for possible 
new indications.
Genomic expression data in combination with in vitro 
drug screening and target verification studies provide insights 
into the mechanisms of action of drugs and thus have become 
widely used in drug repositioning.22–25 Recently, we have 
explored prediction of adverse drug reactions (ADRs) based 
on the drug-induced gene-expression profiles from cultured 
human cells in the Connectivity Map (CMap) database.26 
The results show that drugs inducing comparable ADRs 
generally lead to similar CMap expression profiles. On the 
basis of such ADR–gene expression association, we have 
established prediction models for various ADRs, including 
severe myocardial and infectious events. Drugs with FDA 
boxed warnings of safety liability have been identified. We, 
therefore, suggest that drug-induced gene expression change 
in combination with computational methods may offer a new 
way to facilitate systematic drug safety evaluation and drug 
repositioning.
In another study, we have demonstrated that the on-target 
and off-target effects of drugs could be characterized by 
drug-induced in vitro genomic expression data in CMap.24 In 
some cases, a family of ligands for the same target tends to 
interact with common off-targets, which may help increase 
the efficiency of indication discovery and explain the compli-
cated mechanisms of action for some drugs. We propose that 
CMap expression similarity is a new indicator of drug–target 
interactions, which can be used to increase the productivity 
during drug repositioning process.
Finding novel therapeutics to treat and cure diseases is 
a fundamental challenge in biomedical research due to the 
high cost and failure rate. Drug repositioning is considered 
a promising strategy to revitalize the slowing drug discovery 
pipeline due to shorter development time and lower failure 
and toxicity risks. Although drug repositioning has its intrin-
sic limitations, it represents an alternative pathway to achieve 
therapeutic success in the postgenomic era.
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